30 Jun 2026
Aurobindo Pharma's US arm completed its acquisition of Lannett Company.
Lannett became a wholly owned subsidiary from 29 June. US FTC approval came on 18 June. The deal deepens Aurobindo's generics presence in the United States.
19 Jun 2026
Aurobindo Pharma received FTC approval for its Lannett acquisition, with deal closure expected this month.
Clearing the US antitrust review removes the last gate on a deal that widens Aurobindo's American generics footprint.
04 Jun 2026
Aurobindo Pharma received final US FDA approval for Tofacitinib tablets in 5 mg and 10 mg strengths, the generic of Pfizer's Xeljanz.
Tofacitinib treats rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, adding to Aurobindo's 550-plus final US approvals that anchor its largest revenue market.